Allergan PLC said early Thursday that it had agreed to acquire the private eye care biotechnology company ForSight VISION5 for $95 million.
The deal also includes a launch milestone payment for the biotech’s lead product, which is inserted on the surface of the eye and allows for the extended release of glaucoma medication, and completed mid-stage clinical trials last year.
The purchase is expected to be completed within 60 days. Allergan shares rose 13.2% over the last three months, compared with a 5.4% rise in the S&P 500.
By Emma Court
The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.
BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.
Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.